GHRH (Growth Hormone Releasing Hormone) Research Overview (also known as Growth Hormone Releasing Hormone, Somatocrinin, GRF, hGHRH(1-44), Modified GRF(1-29), Sermorelin (1-29 analog), GHRH(1-44))
Growth Hormone Releasing Hormone (GHRH) is a 44-amino acid hypothalamic peptide that stimulates growth hormone (GH) secretion from the anterior pituitary by binding to GHRH receptors on somatotroph cells. Endogenous GHRH is released in pulses, driving the pulsatile nature of GH secretion, and has an extremely short plasma half-life of 2-4 minutes due to rapid DPP-IV cleavage. Research analogs like Modified GRF(1-29) (also known as CJC-1295 without DAC) provide enhanced stability while preserving the physiological pulsatile GH release pattern, making GHRH-based research protocols a cornerstone of GH optimization research.
What Is GHRH (Growth Hormone Releasing Hormone)?
Growth hormone-releasing hormone, abbreviated GHRH, is a hypothalamic peptide that regulates secretion of growth hormone from somatotroph cells in the anterior pituitary. The hormone was isolated and characterized in the early 1980s after investigators identified a hypothalamic factor capable of stimulating pituitary GH release. This work established GHRH as the principal positive hypothalamic regulator of the GH axis, complementing the inhibitory action of somatostatin. The principal human form, often designated hGHRH(1-44), contains 44 amino acids. Its biologic activity is concentrated in the N-terminal region: the first 29 amino acids retain most of the activity needed for receptor binding and stimulation of GH release, whereas the C-terminal region contributes to molecular properties and activity in the native peptide.
Endogenous GHRH is secreted by hypothalamic neurons in a pulsatile, circadian-regulated pattern. These pulses stimulate corresponding GH pulses from the pituitary, particularly during early nocturnal slow-wave sleep. GHRH has an exceptionally short circulating half-life, commonly estimated at approximately 2-4 minutes, because it is rapidly degraded by peptidases including dipeptidyl peptidase-IV (DPP-IV). This instability prompted development of research analogs. Sermorelin is a synthetic version of the active 1-29 fragment. Modified GRF(1-29), commonly called Mod GRF or CJC-1295 without DAC, incorporates substitutions at positions 2, 8, 15, and 27 to improve stability while retaining a relatively short action. CJC-1295 with DAC contains a drug-affinity complex that markedly prolongs exposure, with pharmacokinetic effects lasting days rather than minutes or hours. These compounds illustrate an important distinction between physiological and pharmacological GH stimulation: short-acting GHRH analogs can reinforce discrete GH pulses, whereas long-acting analogs may produce more sustained stimulation and a less natural secretory pattern.
Research Indications
HIV-Associated Abdominal Lipodystrophy
Visceral adipose-tissue reduction
The GHRH analogue tesamorelin has randomized-trial evidence for reducing visceral adipose tissue in people with HIV and excess abdominal fat.
Body-image and waist-related outcomes
Trial programs reported reductions in abdominal fat measures; benefit depends on continued treatment and is not equivalent to generalized weight-loss therapy.
Growth Hormone Axis Stimulation
Physiologic pulsatile GH release
GHRH activates pituitary GHRH receptors and can increase endogenous pulsatile growth-hormone secretion when pituitary reserve is present.
IGF-1 response monitoring
Changes in IGF-1 are a downstream pharmacodynamic marker, but do not by themselves establish a clinical benefit or treatment need.
Liver Fat and Metabolic Research
Hepatic fat in HIV-associated lipodystrophy
Clinical research with tesamorelin has evaluated liver-fat reduction in people with HIV, but results should not be extrapolated to all causes of fatty liver disease.
Body-composition research outside approved settings
Use for healthy-aging, athletic performance, generalized obesity, or cosmetic body recomposition remains inadequately supported and carries GH-axis risks.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| HIV-associated abdominal lipodystrophy | 2 mg | Once daily | Subcutaneous |
| Investigational GH-axis stimulation | Protocol-specific GHRH analogue dose | As directed by study protocol | Subcutaneous |
| Endocrine diagnostic testing | Weight- and assay-specific | Single supervised test dose | IV or subcutaneous |
| Non-approved performance or anti-aging use | No evidence-based dose | Not established | Injectable |
Timing
Approved tesamorelin labeling uses daily subcutaneous administration. Study protocols commonly monitor fasting glucose, IGF-1, clinical response, and adverse effects at baseline and during treatment; timing and dose changes should be clinician-directed.
Peptide Interactions
GHRH and ghrelin-receptor agonists stimulate complementary pathways in GH secretion; combined use can also increase GH/IGF-1-related adverse-effect risk.
Both are GHRH-pathway agents. Combining them is generally duplicative and may raise IGF-1 or fluid-retention risk without established additional benefit.
Concurrent GH can make GH-axis effects harder to interpret and may compound edema, arthralgia, insulin resistance, and elevated IGF-1.
GHRH-driven GH signaling may affect glucose tolerance; people using diabetes therapies require clinician-guided glucose monitoring and medication review.
Glucocorticoids can alter GH-axis physiology and worsen glycemic control, potentially changing response and safety monitoring needs.
Therapies that increase GH/IGF-1 signaling should not be used in active malignancy unless specifically directed by an oncology and endocrinology team.
Reported Research Timeline
01First dose to 24 hours (reported in cited studies): transient injection-site discomfort, headache, flushing, nausea, or no perceptible effect may occur. Acute GH secretion is not a reliable subjective marker.
02Weeks 1–2 (reported in cited studies): clinical protocols may assess tolerability, fasting glucose, and symptoms suggestive of fluid retention or altered glucose handling.
03Weeks 4–8 (reported in cited studies): iGF-1 may be reassessed where clinically indicated. Elevated IGF-1 or worsening glucose control warrants medical review rather than self-adjustment.
04Months 3–6 (reported in cited studies): in studied HIV-associated lipodystrophy populations, changes in visceral-fat measures are generally assessed over months rather than days or weeks.
05Months 6–12 (reported in cited studies): continued benefit and safety require periodic reassessment of abdominal-fat outcomes, glucose status, IGF-1, and contraindications.
06After discontinuation (reported in cited studies): effects on visceral fat may diminish over time. Follow-up should be based on the original indication and clinician-directed monitoring plan.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Do not use GHRH-pathway therapy during active malignancy; review any prior cancer history with an appropriate clinician.
Diabetes, prediabetes, or use of glucose-lowering medication requires glucose monitoring because GH-axis stimulation can worsen glucose tolerance.
Assess IGF-1 periodically when clinically used; persistently elevated values may indicate excessive GH-axis stimulation.
Fluid retention, joint pain, paresthesia, headache, nausea, and injection-site reactions are potential adverse effects requiring review if persistent or worsening.
Avoid use in pregnancy unless specifically prescribed; pregnancy and breastfeeding safety data are insufficient for nonessential use.
Seek Medical Attention If:
You develop facial or throat swelling, widespread hives, wheezing, or other signs of a severe allergic reaction.
You have severe or persistent headache, visual changes, vomiting, or neurologic symptoms.
You experience marked thirst, frequent urination, confusion, or other symptoms of significant hyperglycemia.
An injection site becomes increasingly painful, hot, swollen, drains pus, or is accompanied by fever.
Quality Indicators
Verified Marker
Identity and purity certificate
Request a lot-specific certificate of analysis showing peptide identity and quantitative purity using validated HPLC and mass-spectrometry methods.
Verified Marker
Intact vial labeling and traceability
A quality product has a legible compound name, amount, lot number, expiry or beyond-use date, storage instructions, and traceable manufacturer or pharmacy information.
Verified Marker
Appropriate lyophilized appearance
For lyophilized material, inspect for an intact dry cake or powder without unusual discoloration, visible contamination, compromised stopper, or evidence of moisture exposure.
Acceptable Range
Clear reconstitution and cold-chain handling
After reconstitution according to product instructions, solution should be clear and free of visible particles. Confirm refrigerated storage requirements and do not use material exposed to uncontrolled heat.
Quality Concern
Research-only sourcing or unverifiable sterility claims
Do not treat a research-use product as suitable for injection. Missing sterility/endotoxin documentation, altered labels, particulate solution, or unverifiable batch testing are major concerns.
Research Citations
- Effects of a Growth Hormone-Releasing Factor in Patients with HIV
Falutz, J., Allas, S., Blot, K., et al., 2007, New England Journal of Medicine - Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Adiposity: A Randomized Clinical Trial
Stanley, T. L., Feldpausch, M. N., Oh, J., et al., 2014, JAMA - Tesamorelin for the Treatment of Non-Alcoholic Fatty Liver Disease in People With HIV: A Randomised, Double-Blind, Multicentre Trial
Stanley, T. L., Fourman, L. T., Feldpausch, M. N., et al., 2019, The Lancet HIV - Long-Term Safety and Effects of Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in HIV-Infected Patients With Abdominal Fat Accumulation
Falutz, J., Allas, S., Mamputu, J. C., et al., 2010, Journal of Clinical Endocrinology and Metabolism
Research Focus
growth hormone secretion, pituitary stimulation, GH pulse, GHRH receptor, somatotroph, DPP-IV stability, GH optimization, anti-aging, body composition
Frequently Asked Questions
What should researchers watch for with GHRH (Growth Hormone Releasing Hormone)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with GHRH (Growth Hormone Releasing Hormone)?
First dose to 24 hours (reported in cited studies): transient injection-site discomfort, headache, flushing, nausea, or no perceptible effect may occur. Acute GH secretion is not a reliable subjective marker.
How is GHRH (Growth Hormone Releasing Hormone) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →